ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Algert Global LLC

Algert Global LLC grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 72.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,388 shares of the biotechnology company's stock after buying an additional 86,098 shares during the quarter. Algert Global LLC owned about 0.09% of ADMA Biologics worth $4,086,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Cerity Partners LLC lifted its holdings in shares of ADMA Biologics by 151.4% in the 3rd quarter. Cerity Partners LLC now owns 50,878 shares of the biotechnology company's stock valued at $1,017,000 after buying an additional 30,637 shares during the period. Citigroup Inc. lifted its holdings in shares of ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of ADMA Biologics by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company's stock valued at $48,007,000 after buying an additional 249,412 shares during the period. Intech Investment Management LLC purchased a new position in ADMA Biologics in the 3rd quarter valued at approximately $1,242,000. Finally, Jennison Associates LLC purchased a new position in ADMA Biologics in the 3rd quarter valued at approximately $690,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now owns 449,088 shares in the company, valued at $7,589,587.20. The trade was a 5.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 185,011 shares of company stock valued at $3,255,204 over the last quarter. Insiders own 3.70% of the company's stock.

ADMA Biologics Trading Down 0.2 %

Shares of NASDAQ:ADMA traded down $0.04 during midday trading on Tuesday, reaching $21.43. The company's stock had a trading volume of 1,103,941 shares, compared to its average volume of 3,623,768. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of 77.04 and a beta of 0.64. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The business has a 50 day moving average price of $18.92 and a 200 day moving average price of $15.05. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter last year, the company posted $0.01 earnings per share. Research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.